Your first 90 days
Your first 90 days on Vyndamax for ATTR amyloidosis with cardiomyopathy
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Vyndamax has one of the simplest starts of any drug on this site. There is no REMS form, no required echo and no lab test before the first fill. What stands between the prescription and the first capsule is mostly paperwork, proof of the diagnosis for the insurer and a call from a specialty pharmacy. This page lays out the first 3 months from the FDA label, Pfizer's VynAssist program and one insurer's written rules.
What has to happen before the first bottle ships
Vyndamax is a specialty drug without a REMS, so the first fill waits on an insurance approval and a specialty pharmacy call, not on a safety program form. These are the 6 things in the way, in order.
Proof of the diagnosis, for the insurer
Cigna's policy accepts a technetium pyrophosphate heart scan, a tissue biopsy typed as TTR amyloid, or a genetic test showing a TTR variant.
- It also wants heart imaging that shows the heart is involved, and heart failure that is not NYHA class IV.
- Ask the office which of these is already in your chart.Cigna policy
Vyndamax or Vyndaqel, and why the numbers differ
The label lists 2 doses of the same medicine, Vyndamax 61mg as one capsule or Vyndaqel 80mg as four 20mg capsules.
- It says they are not substitutable on a per mg basis.
- Pfizer says Vyndamax is the only tafamidis option after 2025, and that switching from Vyndaqel will likely need a new prescription and prior authorization.FDA label
A word about Attruby and gene silencers
Cigna's policy will not cover tafamidis taken together with Attruby or with a drug that silences TTR, such as Amvuttra, Onpattro or Wainua.
- The Vyndamax label itself says nothing about combining them.
- If you take one of these now, the cardiologist decides the treatment plan and the insurer decides what it pays for.Cigna policy
A medicine review
The label says tafamidis can raise levels of medicines carried by a transporter called BCRP, such as methotrexate, rosuvastatin and imatinib.
- The Patient Information asks you to list every prescription, over-the-counter medicine, vitamin and herbal supplement.
- Tell the cardiologist about any liver problems too.FDA label
Pregnancy and breastfeeding, raised before day 1
The label says, based on animal studies, that tafamidis may harm an unborn baby.
- It asks prescribers to consider pregnancy planning and prevention, and says breastfeeding is not recommended during treatment.
- The label does not require a pregnancy test before the first dose.FDA label
VynAssist and the specialty pharmacy
Once you sign up for a VynAssist Access Care Manager, Pfizer says the manager calls you to introduce themselves.
- They help you understand your coverage, expected costs and what working with a specialty pharmacy involves.
- They also coordinate with your healthcare team as needed.VynAssist access
The days that matter
Counted from the first dose, with the 30-day refills the carton sets and the yearly insurance renewal, since the label sets no test schedule. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Diagnosis records and the insurance request
The cardiologist's office submits the prior authorization with the scan, biopsy or genetic test result and the heart imaging.
- You can sign up for a VynAssist Access Care Manager at the same time.
The specialty pharmacy calls
Pfizer says Vyndamax goes through 6 national specialty pharmacies and over 175 integrated delivery networks.
- Once the plan approves it, the pharmacy ships it to your home.
First dose, one 61mg capsule
One capsule once a day, swallowed whole and never crushed or cut.
- A carton holds 3 blister cards of 10 capsules, which is 30 days.
Refill, then about every 30 days
The first 30-capsule carton runs out around here, at one capsule a day.
- Under its terms, the Vyndamax copay card cannot be used more than once every 24 days.
- Those posted terms still say the offer expires December 31, 2025.
Refill, number 2
Three months in
The label sets no blood test or scan schedule for Vyndamax.
- In the ATTR-ACT trial the walking test and quality of life scores first favored tafamidis at month 6, and deaths and hospital stays were counted over 30 months.
Refill, number 3
Insurance renewal
Cigna approves tafamidis a year at a time, and other plans set their own length.
- Ask the office when your approval ends so a renewal goes in before it lapses.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Vyndamax label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated May 12, 2026, read from the FDA's label database today. FDA label
- October 2023
The FDA approved removing the patient counseling text about the THAOS registry, an outcomes survey for people with transthyretin amyloidosis. The dose and safety text did not change.FDA letter
- June 2021
Results of a drug interaction study were added. Tafamidis blocks the BCRP transporter and can raise levels of medicines such as rosuvastatin.FDA letter
- May 2019
The FDA approved Vyndaqel and Vyndamax together on May 3rd for adults with ATTR cardiomyopathy, with the same label for both.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- One capsule, once a day, swallowed whole
The label dose is Vyndamax 61mg, one capsule, once a day.
- Capsules are swallowed whole and not crushed or cut.
- The label found no meaningful effect of a high fat meal, and the Patient Information gives no food rule.FDA label
- Not interchangeable with Vyndaqel by weight
One 61mg Vyndamax capsule gave the same blood levels as four 20mg Vyndaqel capsules.
- The cartons warn pharmacists that the 2 are not substitutable on a per mg basis.
- It is worth checking that every refill carton says Vyndamax 61mg.FDA label
- If you miss a dose
The Patient Information says to take it as soon as you remember, or skip it if it is almost time for the next one.
- It says never to take 2 doses at the same time.FDA label
- Medicines Vyndamax can raise
Tafamidis blocks BCRP, which can raise levels of methotrexate, rosuvastatin, imatinib and similar medicines.
- In a study of healthy volunteers, exposure to rosuvastatin roughly doubled on Vyndamax.
- The label tells prescribers to watch for side effects of those medicines and adjust their dose if needed.FDA label
- Thyroid blood tests
The label says tafamidis may lower total thyroxine on blood tests without changing TSH, and no signs of an underactive thyroid were seen.
- Tell anyone reading your thyroid tests that you take Vyndamax.FDA label
- Pregnancy and breastfeeding
Tell your healthcare provider right away about a known or suspected pregnancy.
- The label also asks that pregnancies be reported to Pfizer at 1-800-438-1985.
- The label says breastfeeding is not recommended during treatment with tafamidis.FDA label
- Storage
The label says to store it at room temperature, 68 to 77 degrees Fahrenheit (20 to 25 Celsius), with brief excursions from 59 to 86 degrees permitted.
- The Patient Information says to keep it out of the reach of children.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
What the label does not list
Vyndamax has no boxed warning and no warnings section, so the label names no emergency symptoms of its own.
- The Patient Information says no known side effects happened during treatment in people with ATTR-CM.FDA label
Side effects in the trial
In ATTR-ACT, side effects were about as common on tafamidis as on placebo.
- About 7% of patients on the 80mg Vyndaqel dose stopped because of a side effect, against 6% on placebo.FDA label
Reporting a side effect
Side effects can be reported to Pfizer at 1-800-438-1985 or to the FDA at 1-800-FDA-1088.
- Tell the cardiologist about anything new, including side effects of a medicine Vyndamax can raise.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe Cigna policy below wants the diagnosis confirmed by a heart scan, biopsy or genetic test, heart imaging, and heart failure short of NYHA class IV. A VynAssist Access Care Manager can explain what the plan is asking for and coordinate with the office.Cigna policy
- You already take Attruby or a TTR silencerCigna does not cover tafamidis used alongside Amvuttra, Attruby, Onpattro, Tegsedi or Wainua. Which treatment to use is the cardiologist's decision, and the insurer decides what it pays for.Cigna policy
- The prescription or approval is for VyndaqelDrugs@FDA lists Vyndaqel as discontinued, and Pfizer says a switch to Vyndamax will likely need a new prescription and prior authorization. Cigna also will not cover both forms at once.Vyndaqel FAQ
- The pharmacy is not in your plan's networkThe VyndaLink line, 1-888-222-8475, helps when you and your doctor do not know which specialty pharmacy is in network with your plan. It also helps when coverage was denied and more research is needed.VyndaLink form
- A copay you cannot payCommercial insurance: the copay program, as little as $0 a month, with a maximum of $10,000 to $60,000 a year. Medicare, Medicaid, TRICARE, VA and other government plans are excluded by its terms. Pfizer's posted terms still say the offer expires December 31, 2025, so ask VyndaLink at 1-888-222-8475 whether it runs in 2026. The Pfizer Patient Assistance Program is for uninsured or government-insured patients who qualify.Copay terms
- A new Medicare plan yearPfizer says a Medicare drug plan needs a renewal or new prior authorization for each new year. Its page suggests refilling before December 31st if a refill falls in late December.VynAssist Medicare
Cigna prior authorization policy, March 1, 2026
- Age 18 or older
- The diagnosis confirmed by a technetium pyrophosphate heart scan, a tissue biopsy typed as TTR amyloid, or a genetic test showing a TTR variant
- Heart imaging, such as an echocardiogram or MRI, showing the heart is involved
- Heart failure, but not New York Heart Association (NYHA) class IV
- Prescribed by or in consultation with a cardiologist or an amyloidosis specialist
- Not covered with Amvuttra, Attruby, Onpattro, Tegsedi or Wainua, or with Vyndaqel and Vyndamax together
Approval length. A year at a time.
This policy took effect March 1, 2026 and cites the October 2023 prescribing information, which is the current label text. It still names Vyndaqel, which Drugs@FDA now lists as discontinued. Cigna notes that wild-type disease has no TTR variant, so a genetic test cannot be the confirming test for it. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- An Access Care Manager who explains your coverage and expected costs, and what to expect from the specialty pharmacy
- A Co-Pay Savings Program for commercial insurance, as little as $0 a month, with a $10,000 to $60,000 yearly maximum, not open to Medicare, Medicaid, TRICARE, VA or cash payers. Its full terms page still says the offer expires December 31, 2025
- The Pfizer Patient Assistance Program through VyndaLink (1-888-222-8475), for uninsured or government-insured patients with household income up to 300% of the federal poverty level
- For Medicare, help with plan changes and the Medicare Prescription Payment Plan, which Pfizer requires before its assistance program will consider a Part D patient
- Information on independent third-party financial support, which Pfizer says you must apply to and be denied by before its assistance program will consider you
Details as the drugmaker publishes them. VynAssist financial
Five questions for the pharmacist or the support line
- Is this carton Vyndamax 61mg, and does my prescription match it rather than Vyndaqel?
- I take these medicines. Is any of them, such as rosuvastatin or methotrexate, raised by Vyndamax?
- Is your pharmacy in my insurance network for Vyndamax, and how many days can you send at once?
- When do you call me for the next refill, and how early can it ship?
- If my plan changes in January, what do you need from me before the first fill of the year?
Questions people ask in the first weeks
How long does it take to get Vyndamax after it is prescribed?
There is no fixed number of days for this. There is no REMS, so the wait is mostly the prior authorization and the specialty pharmacy's call. Pfizer says the medicine ships to your home once the plan approves it.
What is the difference between Vyndamax and Vyndaqel?
Vyndamax and Vyndaqel both contain the same medicine, tafamidis. Vyndamax is one 61mg capsule a day and Vyndaqel was four 20mg capsules a day, which gave the same blood levels. The label says they are not substitutable milligram for milligram. Drugs@FDA now lists Vyndaqel as discontinued in the United States.
Do I need blood tests or scans on Vyndamax?
The Vyndamax label sets no required schedule of blood tests or scans. It notes that total thyroxine may read lower on blood tests without a change in TSH. Your cardiologist still decides what follow-up you need for the heart condition itself.
What if I miss a dose of Vyndamax?
The Patient Information says to take it as soon as you remember, or to skip it if the next dose is almost due. It says never to take 2 doses at the same time.
Can I take Vyndamax with Attruby or Amvuttra?
The Vyndamax label does not address combining them. Cigna's policy will not pay for tafamidis alongside Attruby or a TTR silencer such as Amvuttra, Onpattro or Wainua. The cardiologist decides the treatment plan, and the insurer decides what it pays for.
Can Medicare patients use the Vyndamax copay card?
No, the copay card is for private insurance only. Its terms exclude Medicare, Medicaid, TRICARE, VA and other government coverage. Those terms also still say the offer expires December 31, 2025. Pfizer says Medicare Part D out-of-pocket costs are capped at $2,400 in 2027, and its assistance program may help those who qualify.
Free email alert
Hear when the Vyndamax label changes
One email the day the FDA revises the Vyndamax label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Vyndamax only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow ATTR amyloidosis with cardiomyopathy for new trials, FDA decisions and label changes for every treatment.
Sources
- VYNDAQEL- tafamidis meglumine capsule, liquid filled; VYNDAMAX- tafamidis capsule, liquid filled: prescribing information and Patient Information, DailyMed version 15 (text revised October 2023), Pfizer, via DailyMed, May 12, 2026.
- Drugs@FDA: FDA-Approved Drugs, NDA 211996 (VYNDAQEL, marketing status Discontinued), FDA, November 7, 2026.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, November 7, 2026.
- VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, November 7, 2026.
- Financial Assistance | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, November 7, 2026.
- Copay Terms and Conditions | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, November 7, 2026.
- Medicare 2027 | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, November 7, 2026.
- Access Support | VynAssist | VYNDAMAX® (tafamidis) Patient Support, Pfizer, November 7, 2026.
- VynAssist | VYNDAMAX® (tafamidis) HCP Support, Pfizer, November 7, 2026.
- VyndaLink® Enrollment Form (PP-VDM-USA-2396), Pfizer, November 7, 2026.
- VYNDAMAX specialty pharmacy information (PP-VDM-USA-2216, May 2025), Pfizer, May 1, 2025.
- Financial Assistance | VYNDAMAX® (tafamidis) | Safety Info, Pfizer, November 7, 2026.
- Amyloidosis - Tafamidis Products, Drug Coverage Policy IP0149, Cigna, March 1, 2026.
- NDA 211996/S-002 and NDA 212161/S-002 supplement approval letter, THAOS registry text removed, FDA, October 17, 2023.
- NDA 211996/S-001 and NDA 212161/S-001 supplement approval letter, BCRP interaction labeling, FDA, June 1, 2021.
- NDA 211996 and NDA 212161 approval letter, FDA, May 3, 2019.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing cardiologist. Found an error? Use the report link in the footer and it will be checked against the source.